Project Grant K08CA293275
Award Date
9/3/24
Completion Date
8/31/29
Dollars Obligated
$182K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
New York, NY 10016, USA
Similar Awards
This federal Project Grant award of $161,000.00 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program supports a pilot study by the University of Connecticut (UConn) to explore communication about sexuality and intimacy among individuals with metastatic breast cancer (MBC) and their partners. The key objectives of the study are to: 1) identify themes in MBC patients' communication about sexuality and intimacy, 2) determine if specific...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $762,258 to Cedars-Sinai Medical Center to conduct a cluster randomized controlled trial. The project aims to assess whether providing natural language processing (NLP)-based feedback with artificial intelligence (AI) summaries of key treatment tradeoffs to patients and physicians after prostate cancer consultations can improve patient decision-making and physician risk...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will support research at Weill Medical College of Cornell University to investigate the role of the androgen receptor (AR) in both normal prostate cell function and prostate cancer development. The $564,543 award, effective March 1, 2025 through February 28, 2030, will enable the research team to determine the factors that mediate the switch between AR's normal, growth-suppressive...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) provides $327,496 to the University of Missouri System to design and develop implementation interventions aimed at improving the quality of active surveillance for men with favorable-risk prostate cancer. The project, awarded on September 13, 2024, seeks to: 1) assess key implementation determinants, 2) design and tailor interventions to support quality...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $714,317 to the Icahn School of Medicine at Mount Sinai to conduct research on the tumor microenvironment and mechanisms driving prostate cancer progression to metastatic castration-resistant disease. The research aims to: Determine how epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET) signaling within the tumor microenvironment impact anoikis...
The National Cancer Institute (NCI) awarded a $535,334 Project Grant (CFDA 93.396 - Cancer Biology Research) to the Albert Einstein College of Medicine to conduct research on the non-autonomous role of androgen signaling in prostate tumorigenesis. The project aims to investigate how androgen receptor (AR) activation in prostatic stromal cells, specifically those expressing the GLI1 transcription factor, can promote prostate epithelial oncogenesis and tumor development through paracrine signaling...
This federal Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), aims to evaluate dietary changes and a Mediterranean diet intervention among medically underserved men with prostate cancer. The $210,003 award, effective July 2, 2025 through June 30, 2030, will fund a pilot feasibility study of a Mediterranean diet intervention targeting 25 men recently diagnosed with localized prostate cancer at a large safety net...
The National Cancer Institute (NCI) awarded a $386,866 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Regents of the University of Michigan to develop individualized estimates of treatment benefit from hormone therapy for men with prostate cancer. The project aims to integrate models for other-cause mortality risk, distant metastases, and prostate cancer-specific mortality to provide personalized estimates of treatment outcomes, and to develop a web...
This federal Project Grant award for $538,553, provided by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), will support research to define the role of quantitative multiparametric MRI (mpMRI) features and circulating tumor cells (CTCs) as early markers of patient outcomes after radiation therapy (RT) and androgen deprivation therapy (ADT) in prostate cancer patients. The 5-year project, which commenced on April 1, 2025, will be conducted by the University...
This $116,720 federal Project Grant award, provided by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program), will fund research to investigate the molecular basis of the interactions between the protein ABI1 and the androgen receptor (AR) in prostate cancer. The award will be used by the Research Foundation for the State University of New York, doing business as Upstate Medical Center, to conduct biophysical studies to elucidate how ABI1 binds to AR and affects its DNA...